MedTrace Logo

Guselkumab for Overlap Inflammatory Bowel Disease and Spondyloarthritis

NCT07602517 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 75

Last updated 2026-05-22

No results posted yet for this study

Summary

This is an observational study of a prospective cohort of guselkumab-initiating Crohn's Disease (CD) and Ulcerative Colitis (UC) patients to identify new or incident spondyloarthritis. This study will include adult patients aged 18-75 with IBD who are undergoing guselkumab intravenous or subcutaneous induction over a 1-year timeframe.

Conditions

  • Spondyloarthritis
  • Inflammatory Bowel Diseases

Interventions

DRUG

Guselkumab

Guselkumab intravenous or subcutaneous induction.

Sponsors & Collaborators

Principal Investigators

  • David Hudesman, MD · NYU Langone Health

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-20
Primary Completion
2028-05-20
Completion
2029-05-20
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07602517 on ClinicalTrials.gov